Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.

Cancer medicine - 1 May 2016

Latimer Nicholas R, Bell Helen, Abrams Keith R, Amonkar Mayur M, Casey Michelle

Abstract excerpt

Trametinib, a selective inhibitor of mitogen-activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression-free survival compared with chemotherapy in patients with BRAF V600E/K mutation-positive advanced or metastatic melanoma (MM). However, the pivotal clinical trial permitted randomized chemotherapy control group patients to switch to trametinib after disease progression, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dacarbazine
Share to Drug Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Paclitaxel

Share to Pyridones

Share to Pyrimidinones

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27172483
DOI: 10.1002/cam4.643
PMCID: PMC4864810

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.PMID 27172483Read ↗

Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.Semantic proximity Read ↗

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.Semantic proximity Read ↗

An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.Semantic proximity Read ↗

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.Semantic proximity Read ↗

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaSemantic proximity Read ↗

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.Semantic proximity Read ↗

Clinical significance on Switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancerSemantic proximity Read ↗

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).Semantic proximity Read ↗

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.Semantic proximity Read ↗

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.